Molecular Cytogenetics Market worth $4.9 billion by 2028

Molecular Cytogenetics Market in terms of revenue was estimated to be worth $3.1 billion in 2023 and is poised to reach $4.9 billion by 2028, growing at a CAGR of 9.9% from 2023 to 2028 according to a new report by MarketsandMarkets™. The high prevalence of cancer and genetic disorders significantly impacts the increased demand for molecular cytogenetics market. Cancer patients require genetic testing in order to chromogenic changes associated with the tumor. This will lead to an increased need for molecular cytogenetics tests. Thus, the escalating demand for cancer diagnosis has led to a pressing need for technologically advanced devices, which is thereby expected to support the growth of the molecular cytogenetics market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=148469224&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral

In 2022, the kits & reagents segment held the largest share of the molecular cytogenetics market by product segment.

The molecular cytogenetics market is segmented into kits & reagents, instruments, consumables and software & services based on products. The kits & reagents segment accounted for the largest share of the molecular cytogenetics market in 2022. This segment covers the most commonly used products, such as probes, testing kits, fluorescent affinity reagents, scanners, software and amongst others. These products are commonly used in clinical laboratories, research laboratories, academic institutes and pharma & biotech companies. As technologies continue to evolve, the efficiency and accuracy of these products contribute significantly to molecular cytogenetics.

The comparative genomic hybridization segment held the largest share of the molecular cytogenetics market by technique segment in 2022.

The global molecular cytogenetics market is differentiated into comparative genomic hybridization, fluorescence in-situ hybridization, chromogenic in-situ hybridization and other techniques based on techniques. In 2022, the comparative genomic hybridization segment dominated the molecular cytogenetics market. The molecular cytogenetics market in cancer is expected to grow at a high rate owing to the growing focus on targeted cancer treatment.

The cancer segment held the largest share of the molecular cytogenetics market by application segment in 2022.

The global molecular cytogenetics market is differentiated into genetic disorders, cancer, personalized medicine and other applications. In 2022, the cancer segment dominated the molecular cytogenetics market. The molecular cytogenetics market in cancer is expected to grow at a high rate owing to the rising incidence of cancer. With a burgeoning global population, the need for cancer diagnosis has significantly increased due to the increased number of cancer diagnoses and research. Diagnostic and research laboratories are at the forefront of this surge, as they cater to routine use of molecular cytogenetics.

The clinical & research laboratories segment held the largest share of the molecular cytogenetics market by end-user segment in 2022.

The global molecular cytogenetics market is differentiated into clinical & research laboratories, academic research institutes, pharmaceutical & biotechnology companies and other end users. In 2022, the clinical & research laboratories segment dominated the molecular cytogenetics market. The molecular cytogenetics market in clinical & research laboratories is expected to grow at a high rate owing to the increasing penetration of molecular cytogenetics in clinical pathological testing. The expanding network of healthcare institutions directly translates to a substantial market share.

North America is the largest regional market for molecular cytogenetics market.

The market for molecular cytogenetics has been divided into five key geographical regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America held the predominant portion of the molecular cytogenetics market. The dominant share of the molecular cytogenetics market resides in North America, thanks to its advanced healthcare infrastructure and significant investments in healthcare. These factors play a pivotal role in driving the demand for molecular cytogenetics products. Additionally, the anticipated increase in the elderly population and subsequent rise in chronic diseases are expected to further fuel the market's expansion. As the demand for advanced cancer and genetic testing rises, so does the need for precise molecular cytogenetics products to ensure successful and safe procedures.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=148469224&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral

Molecular Cytogenetics Market Dynamics:

Drivers:

1. Increasing incidence of cancer and genetic disorders

Restraint:

1. High cost of advanced instruments

Opportunities:

1. Untapped emerging markets

Challenge:

1. Transition from FISH to array-based techniques

Key Market Players of Molecular Cytogenetics Industry:

The major players operating in this market are Thermo Fisher Scientific Inc. (US), Illumina Inc. (US), Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity (US), Abbott Laboratories (US), Agilent Technologies, Inc. (US), Pacific Biosciences (US), Bio-Rad Laboratories, Inc. (US), Bio-Techne Corporation (US), GeneDx (US), Oncocyte Corporation (US), BioView (Israel), Oxford Gene Technology IP, Limited. (UK), Applied Spectral Imaging, Inc. (US), Cyto-Test Inc. (US), KromaTiD, Inc. (US), Genial Genetic Solutions, Ltd. (UK), Cytognomix, Inc. (Canada), MetaSystems (Germany), SciGene (US), Biomodal (UK), Biocare Medical (US), BioDot (US), OncoDNA (Belgium).

The break-up of the profile of primary participants in the molecular cytogenetics market:

By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
By Designation: C-level - 27%, D-level - 18%, and Others - 55%
By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=148469224&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral

Molecular Cytogenetics Market - Key Benefits of Buying the Report:

The report aims to assist market leaders and new entrants by offering close approximations of revenue figures for both the overall digital therapeutics market and its subsegments. Stakeholders can leverage this report to comprehend the competitive landscape, acquire insights for strategic business positioning, and formulate effective go-to-market strategies. Additionally, it provides stakeholders with the means to assess the market dynamics and furnishes information on crucial market opportunities, restraints, drivers, and challenges.

Contact:

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/molecular-cytogenetic-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/molecular-cytogenetic.asp

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.